Literature DB >> 17870030

Measuring disability and quality of life in established rheumatoid arthritis.

Siri Lillegraven1, Tore K Kvien.   

Abstract

Rheumatoid arthritis is a chronic inflammatory disease with a major impact on physical and psychological health. It can cause severe disability and reduce health-related quality of life, aspects that are important to patients. Thus, it is important to measure disability and health-related quality of life in clinical practice and in clinical trials. This article presents an overview of the most important measures of outcome concerning disability and health-related quality of life, including different forms of the Health Assessment Questionnaire (HAQ, MHAQ, MDHAQ, HAQ II), visual analogue scales for fatigue and function, SF-36, Arthritis Impact Measurement Scales (AIMS/AIMS2), the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire, Nottingham Health Profile, Sickness Impact Profile and the utility instruments 15D, EQ-5D, SF-6D and Health Utilities Index (HUI) 2 and 3.

Entities:  

Mesh:

Year:  2007        PMID: 17870030     DOI: 10.1016/j.berh.2007.05.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  26 in total

1.  Health-related quality of life in young adult patients with rheumatoid arthritis in Iran: reliability and validity of the Persian translation of the PedsQL™ 4.0 Generic Core Scales Young Adult Version.

Authors:  Amir H Pakpour; Isa Mohammadi Zeidi; Fariba Hashemi; Mohsen Saffari; Andrea Burri
Journal:  Clin Rheumatol       Date:  2012-09-11       Impact factor: 2.980

2.  Fatigue and severity of rheumatoid arthritis in Moroccan patients.

Authors:  Yousra Ibn Yacoub; Bouchra Amine; Assia Laatiris; Fahd Wafki; Fatima Znat; Najia Hajjaj-Hassouni
Journal:  Rheumatol Int       Date:  2011-03-30       Impact factor: 2.631

3.  Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey.

Authors:  Marion M G Brands; Deniz Güngör; Johanna M P van den Hout; Francois P J Karstens; Esmee Oussoren; Iris Plug; Jaap Jan Boelens; Peter M van Hasselt; Carla E M Hollak; Margot F Mulder; Estela Rubio Gozalbo; Jan A Smeitink; G Peter A Smit; Frits A Wijburg; Hanka Meutgeert; Ans T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2014-07-22       Impact factor: 4.982

4.  Population Variations in Rheumatoid Arthritis Treatment and Outcomes, Northern California, 1998-2009.

Authors:  Lisa J Herrinton; Leslie Harrold; Craig Salman; Liyan Liu; Robert Goldfien; Maryam Asgari; Joel M Gelfand; Jashin J Wu; Jeffrey R Curtis
Journal:  Perm J       Date:  2015-12-21

5.  OMERACT Quality-adjusted Life-years (QALY) Working Group: Do Current QALY Measures Capture What Matters to Patients?

Authors:  Logan Trenaman; Annelies Boonen; Francis Guillemin; Mickael Hiligsmann; Alison Hoens; Carlo Marra; Will Taylor; Jennifer Barton; Peter Tugwell; George Wells; Nick Bansback
Journal:  J Rheumatol       Date:  2017-03-15       Impact factor: 4.666

6.  Extraarticular manifestations in Turkish patients with rheumatoid arthritis: impact of EAMs on the health-related quality of life in terms of disease activity, functional status, severity of pain, and social and emotional functioning.

Authors:  Filiz Eser; Yeşim Garip; Hatice Bodur
Journal:  Rheumatol Int       Date:  2011-02-16       Impact factor: 2.631

7.  Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis.

Authors:  András Inotai; Bernadette Rojkovich; Angéla Fülöp; Emese Jászay; Tamás Agh; Agnes Mészáros
Journal:  Rheumatol Int       Date:  2011-01-18       Impact factor: 2.631

8.  Health-related quality of life in patients with common rheumatic diseases referred to a university clinic.

Authors:  Karin Laas; Risto Roine; Pirjo Räsänen; Harri Sintonen; Marjatta Leirisalo-Repo
Journal:  Rheumatol Int       Date:  2008-08-06       Impact factor: 2.631

9.  Translation and validation of the Persian version of the Arthritis Impact Measurement Scales 2-Short Form (AIMS2-SF) in patients with rheumatoid arthritis.

Authors:  Ahmad Reza Askary-Ashtiani; Sayed Javad Mousavi; Mohamad Parnianpour; Ali Montazeri
Journal:  Clin Rheumatol       Date:  2009-01-10       Impact factor: 2.980

10.  Anti-cyclic citrullinated peptide antibodies do not reflect self-reported disability and physical health in patients with rheumatoid arthritis of less than 5 years of duration.

Authors:  Chalotte Heinsvig Poulsen; Søren Jacobsen; Morten Frisch; Kirsten Frederiksen; Christoffer Johansen
Journal:  Rheumatol Int       Date:  2013-06-29       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.